Pfizer Keeps Hands On Consumer Product Wheel In Opting Against Split
Executive Summary
Pfizer didn't cite its consumer health business in announcing it will retain current structure, but best-selling Lipitor's cholesterol treatment indication is the most coveted indication yet to be available OTC.
You may also be interested in...
Consumer Business An Asset To Pfizer, A Divestment Chip To Analysts
CEO Ian Read says selling the consumer business has to do more than boost Pfizer's treasury. "If there is a better mix, we are always open to it, but it has to be for strategic reasons rather than cash," he says.
Consumer Business An Asset To Pfizer, A Divestment Chip To Analysts
CEO Ian Read says selling the consumer business has to do more than boost Pfizer's treasury. "If there is a better mix, we are always open to it, but it has to be for strategic reasons rather than cash," he says.
Stronger Together: Pfizer Decides Against A Split
The pharma giant's decision not to break up into two separate publicly traded companies as it has been contemplating for several years reflects an improved growth outlook and the inability to unlock trapped value. Now Pfizer can finally get on with business.